Telesis Bio Inc.: Nasdaq/NYSE listing notice — Telesis Bio receives Nasdaq delisting notice for insufficient stockholders' equity

Telesis Bio Inc.

Received Nasdaq notice for non-compliance with minimum $10M stockholders' equity requirement on April 3, 2024.
Must submit compliance plan by May 20, 2024; may get extension until Sep 30, 2024 if plan accepted.
Common stock continues trading under TBIO on Nasdaq Global Select for now.
2024 Annual Meeting set for May 1, 2024; shareholder proposals due April 18, 2024.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Telesis Bio Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A)

Exact text from the filing

April 3, 2024, Telesis Bio Inc. (the Company) received a letter (the Letter) from the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that, based upon the Company's annual report on Form 10-K which was filed with the Securities and Exchange Commission (SEC) on March 29, 2024, the Company is not in compliance with the minimum stockholder’s equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), which requires companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in sto

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-24-042617

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.